Osteoporosis With Stage 4 CKD: Bisphosphonate or Denosumab First
A single patient whose declining kidney function narrows, rather than opens, her treatment options. The disagreement isn't whether her osteoporosis needs treatment — it does — it's which agent is actually safer once real renal impairment is on the table.
Wanda K., a 70-year-old woman, has lived with hypertension and type 2 diabetes for over two decades, and her kidney function has declined slowly enough over the past several years that she describes it as something she has simply learned to live around rather than something that changed her life all at once. A wrist fracture from a low fall in her kitchen last month — the kind of fall she says she has taken before without consequence — brought her into the workup that found two things at once. The first was a femoral neck T-score of −2.7. The second was an eGFR of 25, down from 41 a year ago: stage 4 chronic kidney disease, and a steeper slope than anyone had been tracking. The fracture is also the first hard evidence that whatever is happening in her bone has crossed out of the realm of a number on a scan.
That eGFR is what removes the group's usual first move before the conversation about her fracture risk even starts. Alendronate's label advises against use below a creatinine clearance of 35 mL/min, and at 25 she is well under that line. Denosumab is not renally cleared, which makes it look like the clean substitute — but "not renally cleared" is a different claim from "no renal-related risk," and the difference is the whole problem. Denosumab carries an FDA boxed warning, added in January 2024 on the strength of Bird and colleagues' analysis of CMS data, for severe hypocalcemia in advanced CKD, with hospitalization, life-threatening events and deaths among the outcomes that drove it. The mechanism is legible in her own labs: a PTH of 112 documents the secondary hyperparathyroidism, and an eGFR of 25 supplies the reduced calcium buffering. Her corrected calcium of 9.1 is normal today, which is precisely how those cases begin. And the label's instruction is not merely to monitor but to evaluate for CKD-mineral bone disorder before initiating, because its presence is what markedly raises the risk — which means the question of what is actually happening in her bone is not a refinement to be settled after starting a drug. It is a precondition of choosing one.
The safer option isn't the risk-free one
Bisphosphonates are effectively off the table at her eGFR — alendronate's label advises against use below a creatinine clearance of 35 mL/min, and at 25 she's well under that line. Denosumab isn't renally cleared at all, which makes it the more straightforward first-line choice here.
I agree bisphosphonates aren't appropriate here, but I don't want denosumab to get treated as automatically safe by comparison. Denosumab carries an FDA boxed warning — added January 2024, on the strength of Bird and colleagues' CMS cohort analysis in JAMA — for severe hypocalcemia in advanced CKD, with hospitalization, life-threatening events and deaths among the outcomes that drove it. The mechanism is exactly what her own labs show: secondary hyperparathyroidism, which her PTH of 112 already documents, plus the reduced calcium buffering that comes with an eGFR of 25.
"Not renally cleared" isn't the same claim as "no renal-related risk" — the mechanism of harm is just different, and it needs active calcium monitoring after each dose, not a one-time check.
Before either drug gets started, I'd want CKD-mineral bone disease ruled out directly — and I'd point out that this isn't only my preference, it's what the Prolia label now instructs: evaluate for CKD-MBD before initiating denosumab in advanced CKD, because its presence is what markedly raises the hypocalcemia risk. Her elevated PTH and declining eGFR are consistent with ordinary osteoporosis, but they're also consistent with renal osteodystrophy — a distinct condition with different bone turnover physiology that changes which drug class is even appropriate.
A bone-turnover marker panel and, if those are ambiguous, a bone biopsy would settle it. Starting an antiresorptive before that workup risks treating the wrong disease process even if the fracture and the T-score both look like straightforward osteoporosis on the surface.
Agreed: hold denosumab until the CKD-mineral bone disease workup returns, start calcitriol and calcium now to correct her secondary hyperparathyroidism ahead of time, and confirm bisphosphonates stay off the table given her eGFR regardless of what the workup shows.
Not agreed: how frequently to monitor calcium after denosumab actually starts — the endocrinologist wanted checks at one and two weeks post-dose given her renal impairment, the primary care physician felt the standard interval was sufficient once PTH is corrected; the more frequent schedule was adopted for the first dose only, to be revisited after.